Gastrointestinal Cancer | Specialty

Understanding Biology and Patient Subsets in HCC

March 22nd 2019

Key Trials Seek to Expand on Efficacy, Tolerability of Treatment Regimens in Refractory CRC

March 22nd 2019

Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.

Dr. Mehta on Immunotherapy in Gastric/GEJ Cancer

March 22nd 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist at Moffitt Cancer Center, discusses the use of immunotherapy in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Leveraging Limited Data in Metastatic Pancreatic Cancer

March 22nd 2019

Damian Laber, MD, provides a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shares his hope for the future of the treatment paradigm.

Dr. Mahipal on Treatment of Newly Diagnosed mCRC

March 22nd 2019

Amit Mahipal, MBBS, professor of medicine, Mayo Clinic, discusses the treatment of patients with newly diagnosed metastatic colorectal cancer.

GI Oncologist Sheds Light on Present and Future of mCRC Treatment

March 21st 2019

Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease.

Novel Drug Targets Stem Cell Activity in Pancreatic Cancer

March 21st 2019

Napabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever conducted in pancreatic ductal adenocarcinoma in the metastatic setting

Immunotherapy Combos May Mark Future of Gastric Cancer Care

March 20th 2019

Rutika Mehta, MD, MPH, discusses the current gastric cancer treatment landscape and sheds light on how emerging therapies could impact the paradigm.

Progress Made in Locally Advanced Pancreatic Cancer

March 19th 2019

Dae Won Kim, MD, highlights recent advances in the neoadjuvant and adjuvant settings for patients with localized pancreatic cancer.

Experts Remain Hopeful About Immunotherapy in HCC

March 19th 2019

Richard Kim, MD, discusses the therapeutic landscape of advanced hepatocellular carcinoma in light of recent findings and highlighted anticipated research in the field.

Chemokine Offers Tempting Target in Tumor Niche

March 19th 2019

Chemokine receptor type 2, a major recruiter of circulating monocytes that subsequently develop into a protumoral type of macrophage within the tumor microenvironment, has emerged as a promising therapeutic target.

Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC

March 18th 2019

The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.

Key Trials Show Utility of Agents Across Therapeutic Classes in Gastric/GEJ Cancer

March 15th 2019

Hope E. Uronis, MD, MHS, sheds light on therapeutic classes in gastric and esophageal cancer and the trials that have demonstrated their utility and refined their applicability across settings, subpopulations, and histologies of gastric/GEJ cancer.

Novel Agents Offer Hope in Hepatocellular Carcinoma

March 15th 2019

Michael A. Morse, MD, FACP, MHS, highlights the latest ongoing research in hepatocellular carcinoma and predicts what future treatment might look like in this field.

Novel Therapeutics, Dosing Strategies Offer Hope in Metastatic Pancreatic Cancer

March 14th 2019

Given the poor prognosis of pancreatic cancer and the steady stream of negative phase III trials, clinicians are facing an uphill battle in the treatment of patients with metastatic pancreatic cancer.

Dr. Strickler on Therapies for Rare Variants of Relapsed/Refractory CRC

March 13th 2019

John Strickler, MD, assistant professor of medicine at Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses therapies for rare variants of relapsed/refractory colorectal cancer.

Key Trials Warrant Consideration in Early-Stage Pancreatic Cancer Paradigm

March 13th 2019

Nilofer Saba Azad, MD, discusses data from 3 recent pivotal trials have influenced practice and/or warrant consideration when treating patients with localized pancreatic cancer.

Despite Progress, Somatostatin Analogs Remain Frontline Standard in NETs

March 13th 2019

Jonathan R. Strosberg, MD, sheds light on the latest developments made in the complex treatment paradigm of gastroenteropancreatic neuroendocrine tumors.

Nab-Paclitaxel Plus Gemcitabine Misses DFS Endpoint in Pancreatic Cancer

March 13th 2019

The adjuvant combination of nab-paclitaxel and gemcitabine was not found to improve disease-free survival compared with gemcitabine alone, as confirmed by independent radiological review, in patients with pancreatic cancer.

Dr. Laber on the PRODIGE 35-PANOPTIMOX Trial in Metastatic Pancreatic Cancer

March 13th 2019

Damian Laber, MD, hematologist/oncologist, senior member, Moffitt Cancer Center, discusses the PRODIGE 35-PANOPTIMOX trial in metastatic pancreatic cancer.